Lanean...
Early Adoption of Dupilumab in the Medicare Population in 2017
Background: In March of 2017, dupilumab became the first FDA approved injectable biologic for treatment of moderate-to-severe atopic dermatitis (AD). As the first drug in this class for AD, dupilumab has revolutionized the disease’s treatment and improved patient outcomes significantly. Previous wor...
Gorde:
| Argitaratua izan da: | Yale J Biol Med |
|---|---|
| Egile Nagusiak: | , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
YJBM
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7757055/ https://ncbi.nlm.nih.gov/pubmed/33380928 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|